NIH has awarded four additional contracts for the development and scaled-up manufacturing of new COVID-19 diagnostic testing technologies through its Rapid Acceleration of Diagnostics Tech (RADx) initiative. The awards total $29.3 million and will help increase testing capacity for COVID-19.
Explore more about: RADx Tech
March 30, 2021
March 1, 2021
An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.
October 6, 2020
NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.
July 23, 2020
In a paper in the New England Journal of Medicine, scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.